Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/16—Purine radicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
  • C07D473/32—Nitrogen atom
  • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/16—Purine radicals
  • C07H19/167—Purine radicals with ribosyl as the saccharide radical
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/582—Recycling of unreacted starting or intermediate materials

Definitions

• the present invention relates to compounds for use in preventing and/or treating
• neurodegenerative diseases or pain, or both.
• United States patent publication No. US20120295863 discloses dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases.
• a selective A 2 A adenosine receptor (A2A ) agonist named CGS21680 has been shown to be able to attenuate Huntington's disease (HD) symptoms in a transgenic mouse model, and rescue the urea cycle deficiency of HD disease by enhancing the activity of the ubiquitin- proteasome system (Chiang et al, 2009 Hum Mol Genet. 18:2929-2942; Chou et al., 2005 J
• Tl-11 ⁇ -( ⁇ hydroxybenzy adenosine, designated as Tl-11 in US20120295863 and also an A 2 AR agonist, has been suggested to have a therapeutic potential in treating neural degenerative diseases.
• Tl-11 it is still difficult to develop Tl-11 as an orally available drug due to its poor bioavailability (F ⁇ 5%).
• Oral bioavailability is an important property in drug development because it represents the percentage of a substance that reaches systemic circulation after absorption and metabolism.
• the invention relates to a compound of formula (1) or (1A):
• the halogen may be located at 3-, 4- or 5-position in formula (I), or at 2-, 4- or 5- position in formula (IA).
• the compound is selected from the group consisting of N 5 - [(3-halothien-2-yl)methyl]adenosine, A ⁇ -[(4-halothien-2-yl)methyl]adenosine, and ⁇ -[(S-halothien- 2-yl)methyl]adenosine.
• the compound is selected from the group consisting of -[(2-halothien-3-yl)methyl]adenosine, ⁇ -[ ⁇ -halothien ⁇ -yljmethylladenosine, and ⁇ -[(5- halothien-3-yl)methyl]adenosine.
• the compound is selected from the group consisting of A ⁇ -KS-bromothien ⁇ -y methylJadenosine, N 6 -[(4-bromothien-2-yl)methyl]adenosine, . ⁇ -[(3-bromothien-2-yl)methyl]adenosine, N 5 -[(5-chlorothien-2-yl)methyl]adenosine, N s -[(4- chlorothien-2-yl)methyl]adenosine, and N 6 -[(3-chlorothien-2-yl)methyl]adenosine.
• the compound is selected from the group consisting of N 6 -[(2-bromothien-3-yl)methyl]adenosine, N 5 -[(4-bromothien-3-yl)methyl]adenosine, ⁇ -[(5- bromothien-3-yl)methyl]adenosine iV 6 -[(2-chlorothien-3-yl)methyl]adenosine, -[(4-chlorothien-3- yl)methyl]adenosine, and A ⁇ -[(5-chlorothien-3-yl)methyl]adenosine.
• the invention relates to a method for preparing the compound of formula (I) or formula (I A) as aforementioned, comprising the step of (I) or ( ⁇ ):
• step (d) removing the protecting groups from the product of step (c) in an acidic condition to afford the compound of formula (I) or (IA).
• the base in step (a) may be diisopropylethylamine.
• the hydroxyl group-protecting agent may be te/7-butyldimethylsilyl chloride.
• the amine group- protecting agent may be Di-/e/7-butyl dicarbonate.
• the base in step (al) may be imidazole.
• step (IXa) the base is diisopropylethylamine and the substituted (thienyl)methanamine is: (i) (5-bromothien-2-yl)methanamine to afford ⁇ -[(5- bromothien-2-yl)methyl]adenosine; or (ii) (5-chlorothien-2-yl)methanamine to afford ⁇ -[(5- chlorothien-2-yl)methyl]adenosine.
• the coupling reaction is preformed in the presence of triphenylphosphine and dii sop ropy 1 azodicarboxylate.
• the substituted (thienyl)methyl group-containing compound may be (5-bromothien-2-yl)methanol.
• the invention relates to a composition
• a composition comprising:
• the invention relates to use of the compound as aforementioned in the manufacture of a medicament for treating a neurodegenerative disease and/or pain in a subject in need thereof.
• the invention relates to the compound as aforementioned for use in treating a neurodegenerative disease and or pain in a subject in need thereof.
• the neurodegenerative disease may be a protein-misfolding disease.
• the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Prion disease, Huntington's disease, and spinal cerebellar ataxias.
• the spinal cerebellar ataxias may be selected from the group consisting of spinal cerebellar ataxias 2, spinal cerebellar ataxias 3, and spinal cerebellar ataxias 7.
• the pain may be acid-induced pain.
• the acid-induced pain may be acid-induced muscle pain.
• the acid-induced muscle pain may be acid-induced chronic muscle pain.
• the pain is selected from the group consisting of
• inflammatory pain cancer pain, chest pain, back pain, neck pain, shoulder pain, migraine, headache, myofascial pain, join pain, muscular pain syndromes, neuropathic pain, peripheral pain, sympathetic pain, postoperative pain, post-traumatic pain, and multiple sclerosis pain.
• the pain may be a dysfunctional pain.
• the dysfunctional pain may be selected from the group consisting of fibromyalgia, myofascial pain, bladder pain syndrome, and a pain caused by irritable bowel syndrome.
• FIG. 1 shows the blood concentrations of T 1 - 1 1 (A) and JMF3464 (B) in ICR mice receiving intravenous (1 mg/kg) or oral (10 mg/kg) of Tl-11 or JMF3464.
• the oral bioavailability of Tl-1 1 and JMF3464 were estimated to be 2.8% and 17.4%, respectively.
• FIG. 2 shows the effects of A 2A R agonists (CGS21680, Tl-1 1, JMF3464, and JMF3818) on serum deprivation-induced cell death.
• Serum-deprived PC 12 cells were treated with or without the indicated reagent(s) for 24 h.
• Cell viability was expressed as a percentage of the results from MTT assays compared to the mean of a serum-containing control group. Data points represent the mean ⁇
• FIGs. 3A-B show the effect of JMF3464 on motor deficits and lifespan.
• J F3464 0.1 1 lag/mouse/day
• JMF1907 0.1 1 g/mouse day
• vehicle CON
• FIGs. 4A-B show the effects of Tl-1 1 in preventing mutant SCA2 gene overexpression-induced protein aggregations and behavioral performance in SC A2 transgenic mice.
• A pSCA2-22Q-EGFP or pSCA2-104Q-EGFP-transfected cells were treated with 10 u Tl-11 or 10 uM JMF1907 (a Tl- 1 1 -derived A2A- agonist) for 24 h. Cells were harvested and subjected to a filter retardation assay or image acquisition.
• B Wild type (WT) or transgenic mice (SCA2) drank water with or without Tl- 1 1. Rotarod performance was used to measure the behavioral function of mice.
• FIGs. 5A-C show that Tl-1 1 ameliorates the motor dysfunction and pontine neuronal death of SCA3 transgenic mice.
• SCA3 transgenic mice were given drinking water containing vehicle (0.2% DMSO) or Tl-11 (0.1 mg ml) beginning at 4 weeks-old.
• Rotarod test showed that compared to wild-type (WT) mice, vehicle-treated 4-month-old ataxin-3-Q79 transgenic mice exhibited a significantly shorter latency to fall and motor incoordination.
• Rotarod performance of Tl-1 1 -treated 4-month-old SCA3 transgenic mice (1 mg per day) was significantly better than that of vehicle-treated ataxin-3-Q79 mice at the same age. Each point shows the mean + S.E. of 7-8 mice.
• FIGs. 6A-C show that JMF1907 alleviates the ataxic symptom and pontine neuronal death of SCA3 transgenic mice.
• A Rotarod test indicated that compared to vehicle-treated 4-month-old SCA3 transgenic mice, rotarod performance of JMF 1 07 -treated 4-month-old SCA3 mice (1 mg per day) was significantly improved. Each point shows the mean + S.E. of 6 mice.
• B-C Immunocytochemical staining of NeuN showed that oral administration of JMF1907 (1 mg per day) significantly prevented neuronal death in the pontine nuclei of a SCA3 mouse at the age of 4 months (SCA3 + JMF1907). Scale bar is 50 ⁇ . Each bar represents the mean + S.E. of 6 mice. * P ⁇ 0.01 compared to SCA3 mice.
• FIGs. 7A-C show that JMF3464 ameliorates the ataxia and pontine neuronal death of SCA3 transgenic mice.
• A SCA3 transgenic mice displayed an impaired rotarod performance. Daily administration of JMF3464 (0.3 mg per day) greatly improved the rotarod performance of 4-month- old SCA3 mice.
• B-C Immunocytochemical staining of neuronal marker NeuN demonstrated that daily oral treatment of JMF3464 (0.3 mg per day) significantly ameliorated neuronal death in the pontine nuclei of a SCA3 transgenic mouse at the age of 4 months. Each bar shows the mean + S.E. of 6 mice. # P ⁇ 0.01 compared to SCA3 transgenic mice.
• FIG. 9 show treatment with JMF3464 reduced TDP-43 mislocalization in NSC34 cells.
• Cells were pretreated with JMF3464 (30 ⁇ ) for one hour, and then treated with AICAR (1 mM, Al) in the presence of JMF3464 for additional 24 hrs.
• TDP-43 (red) localization was analysed by immunostaining. The locations of nuclei were marked by Hochest (blue).
• FIGs. lOA-C show the analgesic effect of JMF3464 on a mouse model of fibromyalgia.
• A-l and A-2) Oral administration of Tl-1 1 showed no analgesic effect on a mouse model of fibromyalgia, in which mice developed chronic muscle pain after intramuscular acid injection and a genistein treatment.
• Open arrows indicate the time mice received acid injection.
• Black arrows indicate the time mice received Tl-11 (p.o.).
• JMF3464 shows an analgesic effect on a mouse model of
• JMF3464 fibromyalgia, in which mice developed chronic widespread pain after treated with intermittent cold stress for 2 days.
• the analgesic effect of JMF3464 is dose-dependent.
• the effective dose started from 100 g/kg (i.p.).
• Oral administration of JMF3464 (1 mg kg) showed an analgesic effect on the intermittent cold stress model.
• treating refers to administration of an effective amount of a therapeutic agent to a subject in need thereof, who has a neurodegenerative disease and/or pain, or a symptom or predisposition toward such a disease and/or pain, with the purpose of cure, alleviate, relieve, remedy, ameliorate, or prevent the disease and/or pain, the symptoms of it, or the
• Such a subject can be identified by a health care professional based on results from any suitable diagnostic method.
• an effective amount refers to the amount of an active compound that is required to confer a therapeutic effect on the treated subject. Effective doses will vary, as recognized by those skilled in the art, depending on rout of administration, excipient usage, and the possibility of co-usage with other therapeutic treatment.
• HED animal dose in mg/kg ⁇ (animal weight in kg human weight in kg) 033 .
• JMF 1907 denotes the compound ⁇ - ⁇ -(indol ⁇ -y ethylladenosine and was disclosed in U.S. patent publication No. 20120295863 Al as compound 6.
• 6-chIoropurine ribofuranoside (2) was treated with an optionally substituted (thienyl)methanamine (3) in the presence of a base to give the desired compound of formula (I).
• a base for example, diisopropylethylamine was used as a base, and the substitution reaction of 6- chloropurine ribofuranoside with (5-bromothien-2-yl)methanamine was carried out by heating in a solvent of 1-propanol to afford ⁇ -[(S-bromothien ⁇ -ylJmethyljadenosine (JMF3464, structure 1).
• (2',3'-O-isopropylidene)adenine (4) was treated with terr-butyldimethyl silyl chloride (TBDMSC1) in the presence of a base imidazole to give a silyl ether derivative (5).
• TBDMSC1 terr-butyldimethyl silyl chloride
• the 6- amino group was protected as a carbamate 6 bearing /e/Y-butoxycarbonyl (Boc) substituent.
• An optionally substituted (thienyl)methyl group was introduced, and the desired compound of formula (I) was obtained after removal of all protecting groups in acidic conditions.
• JMF3464 Binding of the indicated compounds to A 2 A adenosine receptor (A 2 AR) and an adenosine transporter (ENT1) was characterized using standard binding protocols. As shown in Table 1 , JMF3464 bound to the A 2A R and an adenosine transporter - equilibrative nucleoside transporter 1.
• JMF3464 toward A A R was similar to those of Tl-1 1 and JMF1907 (an analogue of Tl-1 1), whereas its affinity toward ENTl was much better than those of Tl-1 1 and JMF1907.
• JMF3818 - ⁇ -[(5-chlorothien-2-yl)methyl]adenosine (JMF3818) also inhibited the apoptosis of PC 12 cells caused by serum withdrawal.
• JMF3818 at 10 u inhibited A 2A receptor and adenosine transporter (ENTl) by 54% and 96%, respectively (FIG. 2).
• JMF3464 exerting beneficial effects on major symptoms of Huntington's disease (HD) in a transgenic mouse model of HD
• FIGs. 5A and 6A Compared to wild-type mice, vehicle-treated SCA3 transgenic mice expressing polyglutamine- expanded ataxin-3-Q79 displayed various ataxic symptoms, including an impaired rotarod performance (FIGs. 5A and 6A) with an onset age of about 3-4 months. As shown in FIGs. 5A and 6A, 4 month-old SCA3 transgenic mice treated with daily oral administration of Tl-11 (1 mg per day) or JMF1 07 (1 mg per day) exhibited a significantly improved rotarod performance. Similar to SCA3 patients, a prominent neuronal death was found in the pontine nuclei of SCA3 transgenic mice (FIGs 5B and 6B).
• JMF3464 has a much higher bioavailability. Therefore, JMF3464 was also expected to exert a beneficial effect on mutant ataxin-3-Q79-induced ataxia and neurodegeneration in SCA3 transgenic mice. As expected, daily application of JMF3464 (0.3 mg per day) alleviated the ataxia (FIG. 7A) and pontine neuronal death (FIGs. 7B and 7C) of SCA3 transgenic mice.
• JMF3464 an analogue of Tl-11 and JMF1907, has a much higher bioavailability. Therefore, JMF3464 is expected to exert a beneficial effect in ALS mice. Treating NSC34 cells with JMF3464 normalized TDP-43 mislocalization caused by AMPK activation (FIG. 9), which supports the notion that JMF3464 is capable of preventing the initial step of ALS pathogenesis. These findings support that JMF3464 exhibits beneficial effects on ALS.
• Tl-1 1 (i.p.) showed excellent analgesic effects on 2 mouse models of fibromyalgia
• Tl-1 1 (up to 2 mg kg) showed no analgesic effect on an acid-induced chronic widespread pain model, in which mice developed fibromyalgia-like pain after intramuscular acid injection and a genistein treatment (FIG. 10A).
• JMF3464 an analogue of Tl-11, showed an analgesic effect on a mouse model of fibromyalgia, in which mice developed chronic widespread pain after being treated with an intermittent cold stress for 2 days (FIG. 10B). Consistent with its good bioavailability, oral administration of JMF3464 (1 mg kg) showed an analgesic effect on the intermittent cold stress model (FIG. 1 OC).
• NMR spectra were obtained on Varian Unity Plus-400 (400 MHz) and chemical shifts ( ⁇ ) were recorded in parts per million (ppm) relative to ⁇ ⁇ 7.24/ 6c 77.0 (central line oft) for CHC1 3 CDC1 3 , ⁇ ⁇ 2.05/ ⁇ 29.92 for (CH 3 ) 2 CO/(CD 3 ) 2 CO, 8H 3.31/ 5c 49.0 for CH3OH/CD3OD, and ⁇ , ⁇ 2.49 (m) /6c 39.5 (m) for (CH 3 ) 2 SO/(CD 3 ) 2 SO.
• splitting patterns are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). Coupling constants ( ) are given in Hz.
• the ESI-MS experiments were conducted on a Bruker Dal tonics BioTOF III high-resolution mass spectrometer. Analytical thin-layer
• Method B A mixture of (5-bromothien-2-yl)methanamine (768 mg, 4 mmol), 6-chloropurine ribofuranoside (143 mg, 0.5 mmol), and diisopropylethylamine (2 mL, 12 mmol) in 1-propanol (20 mL) was heated at 70 °C for 7 h.
• CEM Discover focused monomode microwave reactor
• ribofuranoside (214 mg, 0.75 mmol), and diisopropylethylamine (3 mL, 18 mmol) in 1-propanol (30 mL) was heated at 70 °C for 7 h.
• the mixture containing the desired product and unreacted (3- bromothien-2-yl)methanamine was treated with di-/er/-butyl dicarbonate (1.4 mL, 6 mmol) in THF (8 mL) and NaHC0 3 ( 1 g, 1.2 mmol) at room temperature for 2 h.
• Tl-1 1 blood samples were collected at 2, 10, 30, 60, 120, 360 minutes after intravenous administration and at 15, 30, 45, 60, 120, 360 minutes after oral administration.
• JMF3464 the blood samples were collected at 2, 10, 30, 60, 120, 240, 360, 480 minutes after intravenous administration and at 15, 30, 60, 90, 120, 240, 360, 480 minutes after oral administration.
• the blood samples were extracted by methanol with 0.1% formic acid, and then 10 uL of the extracted samples were injected to UPLC-MSMS to for quantitation.
• the pharmacokinetic parameters were obtained using a pharmacokinetic program WinNonlin, fitting data to a noncompartmental model.
• the pharmacokinetic parameters including the area under the plasma concentration-versus-time curve (AUC) to the last sampling time, (AUC0 1 20), to the time infinity (AUC C *.), the terminal-phase half-life (T 1 / 2 ), the maximum concentration of compound in plasma (C max ), the time of Cmax (T max ), and the first order rate constant associated with the terminal portion of the curve (k) were estimated via linear regression of time vs. log concentration.
• the total plasma clearance (CL) was calculated as dose/AUCj. v ..
• the oral bioavailability ( ) of the test compound by oral administration was calculated from the AUCo « > of the oral dose divided by the AUCo ⁇ c Of the i.v. dose.
• Radioligand binding assays were performed by MDS Pharma Services Taiwan (Taipei, Taiwan) using standard binding protocols.
• a ⁇ A binding assays membrane proteins collected from HEK293 cells overexpressing human A2 A R were incubated in the reaction buffer [50 mM Tris-HCl (pH 7.4), 10 mM MgCl 2 , 1 mM EDTA, and 2 U/mL adenosine deaminase] containing 3 H-CGS21680 (50 nM) for 90 min at 25 °C. Nonspecific binding was assessed in the presence of 50 uM adenosine-5'-JV-ethylcarboxamide.
• Binding assays for adenosine transporters were conducted as described earlier. Membrane fractions collected from the cerebral cortex of Duncan Hartley-derived guinea pigs were incubated with 3 H-labeled 6-[(4-nitrobenzyl)thio]-9- -D-ribofuranosylpurine (NBTI, 0.5 nM) for 30 min at 25 °C in the incubation buffer containing 50 mM Tris-HCl (pH 7.4). Nonspecific binding was assessed in the presence of 5 ⁇ NBTI, an effective inhibitor of
• NBTI is a high-affinity inhibitor of ENT1 , and inhibits only human (h)ENTl at 0.5 nM. Reactions were terminated by filtration over GF/B glass fibers and washing with the reaction buffer.
• Ceil culture and transient transection Rat PC 12 cells purchased from American Type Culture Collection (ATCC; Manassas, VA, USA) were maintained in DMEM supplemented with 10% horse serum and 5% FBS and incubated in a CO 2 incubator (5%) at 37 °C.
• LIPOFECTAMTNETM 2000 (Invitrogen) was used as a vehicle to transfer plasmids into cells according to the manufacture's protocol. Plasmids were kindly provided by Dr. Pulst (Department of Neurology, University of Utah, USA). Normally, 5 ⁇ g of DNA combined with 5 ⁇ of LIPOFECT AMINETM 2000 was applied to each well of 6-well plates. The plating number was (1 ⁇ 1.5) x 10 6 cells/well. After transfections for 6 h, cells were treated with reagents for another 24 h. Images were taken with a Zeiss Axi overt 200M inverted fluorescence microscope (Gottingen, Germany).
• MTT assay survival was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) metabolism assay. In brief, after treatment, MTT was added to the medium
• mice Male R6/2 mice (Mangiarini et al., 1996 Cell. 87:493-506) and littermate controls were originally obtained from Jackson Laboratories (Bar Harbor, ME, USA), and mated to female control mice (B6CBAFI/J).
• Offspring were identified by a polymerase chain reaction (PCR) genotyping technique of genomic DNA extracted from tail tissues using primers located in the transgene (5 ' -CCGCTC AGGTTCTGCTTTTA-3 ' ; SEQ ID NO: 1, and 5'- GGCTGAGGA AGCTGAGGAG-3 ' ; SEQ ID NO: 2) to ensure that the number of CAG repeats remained approximately 150.
• Animals were housed at the Institute of Biomedical Sciences Animal Care Facility under a 12/12-h light/dark cycle. Body weights of mice were recorded once daily.
• Rotarod performance Motor coordination was assessed using a rotarod apparatus (UGO BASILE, Comerio, Italy) at a constant speed (12 rpm) over a period of 2 min (Carter et al., 1999 J Neurosci. 19:3248-3257). All mice were trained for 2 days at the age of 4 weeks to allow them to become acquainted with the rotarod apparatus. Animals were then tested three times per week at the ages of 4-12 weeks. For each test, animals were placed in the apparatus before initiation of rotation. Latency to fall was recorded automatically. Each mouse was given three trials for a maximum of 2 min for each trial.
• EXAMPLE 4 Animals The C57BL/6 mice were purchased from National Laboratory Animal Center (Taiwan). The transgenic mice (ATAXN2® 127 ) were provided by Dr. Pulst. Mice were kept in a soundproof room under a 12/12 h light/dark cycle and controlled temperature (22 ⁇ 2°C). Food and water were available ad libitum. All efforts were made to minimize the number of animals used and their pain and discomfort, according to the principles and directives of the NIH Guide for the Care and Use of Laboratory Animals. These experiments were also reviewed and approved by the Institutional Animal Care and Use Committee at the National Research Institute of Chinese Medicine (Approval No: 100-15).
• Equal protein concentrations (15 ⁇ 20 ⁇ g well) in each group were filtered through a 2% sodium dodecyl sulfate (SDS)-pre-equilibrated cellulose-acetate membrane (0.2 ⁇ ; Whatman, Maidstone, Kent, UK) using the Bio-Dot SF Apparatus (Bio-Rad, Hercules, CA, USA). During suction, each well was washed with 200 ⁇ 0.1% SDS twice.
• SDS sodium dodecyl sulfate
• the blot was blocked in TBS (100 mM Tris-HCI and 150 mM NaCl; pH 7.4) containing 3% nonfat dried milk for I h at room temperature and then incubated with anti-polyglutamine (1 :5000; MAB 1574) antibody in 3% bovine serum albumin (BSA) with 0.02% NaN 3 (4 °C overnight) to probe normal and mutant ATAXN2.
• TBS 100 mM Tris-HCI and 150 mM NaCl; pH 7.4
• anti-polyglutamine (1 :5000; MAB 1574) antibody in 3% bovine serum albumin (BSA) with 0.02% NaN 3 (4 °C overnight) to probe normal and mutant ATAXN2.
• BSA bovine serum albumin
• Rotarod performance The wild type and transgenic mice at the age of 5 weeks old were used in this study. Motor coordination was assessed using a rotarod apparatus (UGO BASILE, Comerio, Italy) at an accelerated speed (10 to 28 rpm) over a period of 5 min. All mice were trained for 2 days within the age of 5 weeks to allow them to become acquainted with the rotarod apparatus. Besides, in this week part of the transgenic mice were started to take Tl-1 1 dissolving in their daily drinking water. Animals were then formally tested 2 times per week from the age of 6 weeks. For each test, animals were placed in the apparatus before initiation of rotation. Latency to fall was automatically recorded. Each mouse was given 2 trials per time. Mice were permitted to rest for 20 ⁇ 30 min between trials.
• mice Balance and coordination functions of mice were determined by performing rotarod test. Mice were placed on the moving drum of a rotarod apparatus (Accelerating Model, Ugo Basile Biological Research Apparatus), which was then accelerated until mouse fell from the drum onto a plate to stop the timer. Latency to fall was measured in four daily trials over the course of 4 days.
• a rotarod apparatus Accelelerating Model, Ugo Basile Biological Research Apparatus
• Transgenic mice B6SJL-Tg(Prnp-TARDBP)4Jlel/J were purchased from the Jackson Laboratory (Bar Harbor, Maine USA), and bred by the National Laboratory Animal Center in Tainan.
• the transgenic mice were screened by PCR with a forward primer 5'-GGT GGT GGG ATG AAC TTT GG-3' (SEQ ID NO: 3) and a reverse primer 5'-GTG GAT AAC CCC TCC CCC AGC CTA GAC-3' (SEQ ID NO: 4).
• the wild type mice were non-transgenic littermates.
• Grip strength The grip strength was measured with Grip Strength-Meter (TSE Systems, Inc., MO, USA). Briefly, a mouse was hand-picked by its tail and allowed to grasp a height-adjustable grip mounted on a force sensor. A pulling force was applied to the mouse by its tail. The maximum force was shown on a digital display panel of a connected control unit when the mouse released its grip. Each mouse was repeatedly tested 3 times.
• Rotarod performance The motor coordination of wild type and transgenic mice was assessed using an apparatus (UGO BASn_E, Comerio, Italy) at constant speed (40 rpm) for 120 seconds. All mice were trained for 2 days per week for 2 weeks. Mice were then formally tested 2 times per week from the age of 9 weeks. For each test, animals were placed in the apparatus before initiation of rotation. Latency to fall was automatically recorded. Each mouse was given 3 trials per time. Mice were permitted to rest for 20 min between trials. Cell culture and transfection. The motor neuron cell line (NSC34) was a generous gift from Dr.
• mice Female C57BL6N mice aged 8-12 weeks were purchased from BioLASCO (Yi-Lan, Taiwan).
• the fibromyalgia model was modified from the acid-induced chronic pain model established by Sluka's group (Sluka et al., 2003 Pain. 106:229-239).
• mice were briefly anesthetized with 2% vaporized isoflurane and received an i.m. injection of 20 ⁇ L ⁇ genistein (1 ⁇ ) in the left gastrocnemius muscle. After 3 minutes, an injection of 20 uL acid saline
• mice (pH 4.0) was given to the same site. The mice then developed long-lasting mechanical hyperalgesia for more than 2 weeks. Analgesic effects of Tl-1 1 (p.o. with an 0.9-mm /7-cm gavage) were tested 4 days after mice had developed the mechanical hyperalgesia. Mechanical hyperalgesia was assayed by testing the withdrawal response of mouse hindpaws to 0.2-mN von Frey filament stimulation.
• the fibromyalgia model was developed by Ueda's group, in which mice were treated with intermittent cold stress for 2 days (Nishiyori and Ueda, 2008 Mol Pain.
• mice treated with intermittent cold stress developed long-lasting (>2 weeks) mechanical and thermal hyperalgesia.
• Analgesic effects of JMF3464 i.p. or p.o. were tested in these mice 5 days after intermittent cold stress.
• Mechanical hyperalgesia was assayed by testing the withdrawal response of mouse hindpaws to 0.2-mN von Frey filament stimulation.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Neurology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Psychology (AREA)
• Pain & Pain Management (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Rheumatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Publications (1)

Family

ID=52993493

Family Applications (1)

Country Status (14)

Cited By (4)

Families Citing this family (2)

Citations (3)

Family Cites Families (6)

• 2014
  • 2014-10-22 SG SG11201603063WA patent/SG11201603063WA/en unknown
  • 2014-10-22 JP JP2016525563A patent/JP6534997B2/ja active Active
  • 2014-10-22 EP EP14855465.2A patent/EP3060566B1/en active Active
  • 2014-10-22 MX MX2016005174A patent/MX367707B/es active IP Right Grant
  • 2014-10-22 US US15/031,711 patent/US10301348B2/en active Active
  • 2014-10-22 KR KR1020167013624A patent/KR102313314B1/ko active Active
  • 2014-10-22 CA CA2927699A patent/CA2927699C/en active Active
  • 2014-10-22 AU AU2014340114A patent/AU2014340114B2/en active Active
  • 2014-10-22 CN CN201480058727.3A patent/CN106414456B/zh active Active
  • 2014-10-22 BR BR112016008901-4A patent/BR112016008901B1/pt active IP Right Grant
  • 2014-10-22 RU RU2016118282A patent/RU2695358C2/ru active
  • 2014-10-22 WO PCT/US2014/061734 patent/WO2015061426A1/en not_active Ceased
• 2016
  • 2016-04-13 IL IL245103A patent/IL245103B/en active IP Right Grant
  • 2016-05-10 ZA ZA2016/03118A patent/ZA201603118B/en unknown

Patent Citations (3)

Non-Patent Citations (13)

Also Published As

Similar Documents

Legal Events